Fina Biotech

Executive Summary

Fina Biotech is a Spanish diagnostics company based in Barcelona, focused on non-invasive detection of bladder cancer through its lead product, UROBEST®. The company has achieved regulatory approval (stage: Approved) and is positioned in the rapidly growing liquid biopsy market. UROBEST® offers a urine-based alternative to invasive cystoscopy, addressing a significant unmet need for early detection and monitoring of bladder cancer, which is the tenth most common cancer worldwide. With an aging population and increased screening awareness, the addressable market is substantial. Fina Biotech also has a pipeline of additional diagnostic projects aimed at expanding its portfolio beyond bladder cancer, though details are limited. The company is privately held and has not disclosed funding or valuation, but its approved status suggests commercial traction in Spain and possibly other European markets.

Upcoming Catalysts (preview)

• Q4 2026FDA 510(k) submission or clearance for UROBEST® in the US60% success
• Q2 2026Publication of new clinical data supporting expanded use of UROBEST® (e.g., monitoring recurrence)75% success
• Q3 2026Commercial partnership or distribution agreement for European markets outside Spain80% success